Pharmaceuticals, Biotechnology and Life Sciences
Realm Therapeutics has submitted its first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for PR022, as a novel treatment for atopic dermatitis (AD).
Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
The fourth quarter was a continuation of the strong performance and business momentum AbbVie has delivered since becoming an independent company in 2013.
FDA found that certain teething tablets for children sometimes exceed the amount of belladonna – a toxic substance – and has asked the company that makes them to recall such medicine.
Bristol-Myers Squib on Thursday posted fourth quarter net earnings of $1.1 billion, driven ly by increased sales of Opdivo and Eliquis.
BD (Becton, Dickinson and Company) has launched its new BD Institute for Medication Management Excellence, developed to help advance the safe and efficient management of medication across the continuum of care.
Ironwood Pharmaceuticals and Allergan have won U.S. Food and Drug Administration’s (FDA) approval for 72 mcg dose of Linzess (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.
AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US
Here’s a lightly edited version of the interview with Dr. Joseph Gulfo, the executive director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University, the author of “Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances” and the former President and CEO of the medical device firm MELA Sciences: